Barr Loestrin generics
Executive Summary
Barr launches generic versions of Loestrin following Sept. 18 approval of ANDA for norethindrone/ethinyl estradiol/ferrous fumarate tablets (Loestrin Fe). Generics of Loestrin 21 (norethindrone/ethinyl estradiol) were approved May 30. Barr's generics will be marketed as Junel 21 and Junel Fe. The company recently announced a deal to acquire rights to the Loestrin family from Galen (1"The Pink Sheet" Sept. 15, 2003, p. 37)...
You may also be interested in...
Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal
A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: